West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter. Asian Pacific Journal of Cancer Prevention 1513-7368 15 23 2014 12 01 Aprepitant in the Prevention of Vomiting Induced by Moderately and Highly Emetogenic Chemotherapy 10045 10051 30222 EN Journal Article 1970 01 01 Chemotherapy is a major therapeutic approach for malignant neoplasms; however, due to the mostcommon adverse events of nausea and vomiting, scheduled chemotherapeutic programs may be impeded oreven interrupted, which severely impairs the efficacy. Aprepitants, 5-HT3 antagonists and dexamethasone areprimary drugs used to prevent chemotherapy-induced nausea and vomiting (CINV). These drugs have excellentefficacy for control of acute vomiting but are relatively ineffective for delayed vomiting. Aprepitant may remedythis deficiency. Substance P was discovered in the 1930s and its association with vomiting was confirmed in the1950s. This was followed by a period of non-peptide neurokinin-1 (NK-1) receptor antagonist synthesis andinvestigation in preclinical studies and clinical trials (phases Ⅰ, Ⅱ and Ⅲ). The FDA granted permission for theclinical chemotherapeutic use of aprepitant in 2003. At present, the combined use of aprepitant, 5-HT3 antagonistsand dexamethasone satisfactorily controls vomiting but not nausea. Therefore, new therapeutic approaches anddrugs are still needed. https://journal.waocp.org/article_30222_63787c1412599ba9898d352e172f9576.pdf